IP Library › Granted Patent US 10,364,238
Granted Patent B2
US 10,364,238 · App. 15/527,923 · Granted Jul 30, 2019

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Inventors: Rebecca Louise Davie (Salisbury, GB); Hannah Joy Edwards (Salisbury, GB); David Michael Evans (Salisbury, GB); Simon Teanby Hodgson (Bedfordshire, GB)
Assignee: Kalvista Pharmaceuticals Limited
C07D413/14A61P43/00C07D231/14C07D401/06C07D401/10C07D401/14C07D403/10C07D409/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,364,238
App. No.
15/527,923
Granted
Jul 30, 2019
Kind
B2
Abstract

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Claims (24)

1. A compound that is:

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1 that is:

or a pharmaceutically acceptable salt or solvate thereof.

3. The compound of claim 1 that is:

or a pharmaceutically acceptable salt or solvate thereof.

4. The compound of claim 1 that is:

or a pharmaceutically acceptable salt or solvate thereof.

5. The compound of claim 1 that is:

or a pharmaceutically acceptable salt or solvate thereof.

6. The compound of claim 1 that is:

or a pharmaceutically acceptable salt or solvate thereof.

7. The compound of claim 1 that is:

or a pharmaceutically acceptable salt or solvate thereof.

8. The compound of claim 1 that is:

or a pharmaceutically acceptable salt or solvate thereof.

9. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

10. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

11. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

12. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

13. A pharmaceutical composition comprising a compound of claim 5 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

14. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

15. A pharmaceutical composition comprising a compound of claim 7 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

16. A pharmaceutical composition comprising a compound of claim 8 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

Assignments (7)
ASSIGNMENT OF SECURITY INTEREST Recorded Jan 15, 2026
From: KALVISTA PHARMACEUTICALS LIMITED; DRI HEALTHCARE ACQUISITION LP
To: DRI UK LP
Reel/Frame 074410/0366 →
SECOND AMENDMENT TO THE PURCHASE AND SALE AGREEMENT DATED MAY 22, 2025 Recorded Jan 15, 2026
From: DRI HEALTHCARE ACQUISITIONS LP; KALVISTA PHARMACEUTICALS LIMITED; KALVISTA PHARMACEUTICALS INC.
To: DRI UK LP
Reel/Frame 074387/0900 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2026
From: DRI HEALTHCARE ACQUISITIONS LP
To: DRI UK LP
Reel/Frame 073489/0961 →
SECURITY INTEREST Recorded Nov 11, 2024
From: KALVISTA PHARMACEUTICALS LIMITED
To: DRI HEALTHCARE ACQUISITIONS LP
Reel/Frame 069334/0267 →
CHANGE OF ASSIGNEE ADDRESS Recorded May 15, 2019
From: KALVISTA PHARMACEUTICALS LIMITED
To: KALVISTA PHARMACEUTICALS LIMITED
Reel/Frame 050174/0659 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2017
From: HODGSON, SIMON TEANBY
To: KALVISTA PHARMACEUTICALS LIMITED
Reel/Frame 042660/0916 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2017
From: DAVIE, REBECCA LOUISE; EDWARDS, HANNAH JOY; EVANS, DAVID MICHAEL
To: KALVISTA PHARMACEUTICALS LIMITED
Reel/Frame 042661/0025 →
Priority Claims (1)
GB 1421083.5 · Nov 27, 2014 · national
Continuity (1)
Related Publication 20180319782A1 · Nov 8, 2018